Elevated Fas Expression Is Related to Increased Apoptosis of Circulating CD8+ T Cell in Patients With Gastric Cancer

Journal of Surgical Research

Volumn 148, Issue 2, 2008, Pages 143-151

  Yoshikawa, Toshiaki ^a   Saito, Hiroaki ^a   Osaki, Tomohiro ^a   Matsumoto, Sachiko ^a   Tsujitani, Shunichi ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

apoptosis; CD8+ T lymphocytes; Fas; Fas ligand; gastric cancer

Indexed keywords

CASPASE 3; FAS ANTIGEN; FAS LIGAND; LIPOCORTIN 5;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INVASION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN BINDING; STOMACH CANCER; STOMACH SURGERY; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; CASPASE 3; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; UP-REGULATION;

EID: 46249123397     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.07.011     Document Type: Article

References (39)

1. Garrido F., Cabrera T., Concha A., et al. Natural history of HLA expression during tumor development. Immunol Today 14 (1993) 491
2. Tanaka Y., and Tevethia S.S. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J Immunol 140 (1988) 4348
3. Restifo N.P., Esquivel F., Kawakami Y., et al. Identification of human cancers deficient in antigen processing. J Exp Med 177 (1993) 265
4. Tada T., Ohzeki S., Utsumi K., et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 146 (1991) 1077
5. Matsuda M., Salazar F., Petersson M., et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J Exp Med 180 (1994) 2371
6. Finke J.H., Zea A.H., Stanley J., et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53 (1993) 5613
7. Zea A.H., Curti B.D., Longo D.L., et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1 (1995) 1327
8. Kono K., Ressing M.E., Brandt R.M., et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2 (1996) 1825
9. Nakagomi H., Petersson M., Magnusson I., et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53 (1993) 5610
10. Lai P., Rabinowich H., Crowley-Nowick P.A., et al. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2 (1996) 161
11. Reichert T.E., Day R., Wagner E.M., et al. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58 (1998) 5344
12. Hoffmann T.K., Muller-Berghaus J., Ferris R.L., et al. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8 (2002) 1787
13. Almand B., Resser J.R., Lindman B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6 (2000) 1755
14. Hoffmann T.K., Dworacki G., Tsukihiro T., et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8 (2002) 2553
15. Reichert T.E., Strauss L., Wagner E.M., et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8 (2002) 3137
16. Bauernhofer T., Kuss I., Henderson B., et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33 (2003) 119
17. Gastman B.R., Atarshi Y., Reichert T.E., et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59 (1999) 5356
18. Nakashima M., Sonoda K., and Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 5 (1999) 938
19. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8 (2002) 793
20. Xu T., Shu C.T., Purdom E., Dang D., et al. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res 64 (2004) 3661
21. Hahne M., Rimoldi D., Schroter M., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274 (1996) 1363
22. O'Connell J., O'Sullivan G.C., Collins J.K., et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184 (1996) 1075
23. Siegel R.M., Martin D.A., Zheng L., et al. Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J Cell Biol 141 (1998) 1243
24. Boon T., Cerottini J.C., Van den Eynde B., et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12 (1994) 337
25. Tureci O., Sahin U., and Pfreundschuh M. Serological analysis of human tumor antigens: Molecular definition and implications. Mol Med Today 3 (1997) 342
26. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immuno-editing: From immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991
27. Whiteside T.L. Immune responses to malignancies. J Allergy Clin Immunol 111 (2003) S677
28. Ries L., Eisner M., and Kosary C. SEER Cancer Statistics Review, 1975-2000 (2003), National Cancer Institute, Bethesda, MD
29. Takahashi A., Kono K., Amemiya H., et al. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin Cancer Res 7 (2001) 74
30. Ichihara F., Kono K., Takahashi A., et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9 (2003) 4404
31. Osaki T., Saito H., Yoshikawa T., et al. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 13 (2007) 382
32. Krammer P.H. CD95's deadly mission in the immune system. Nature 407 (2000) 789
33. Stuart P.M., Griffith T.S., Usui N., et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 99 (1997) 396
34. Bechmann I., Mor G., Nilsen J., et al. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 27 (1999) 62
35. Orlinick J.R., Elkon K.B., and Chao M.V. Separate domains of the human Fas ligand dictate self-association and receptor binding. J Biol Chem 272 (1997) 32221
36. Kayagaki N., Kawasaki A., Ebata T., et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182 (1995) 1777
37. Mizutani Y., Hongo F., Sato N., et al. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 92 (2001) 287
38. Nagao M., Nakajima Y., Hisanaga M., et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?. Hepatology 30 (1999) 413
39. Song E., Chen J., Ouyang N., Su F., et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 85 (2001) 1047